Raymond James Financial Services Advisors, Inc. Biotechnology

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
EDIT Editas Medicine, Inc.	$99.7M	$207,000 0.0% of portfolio	60,894	Q3 2024 Reduced 6.46%
GERN Geron Corp	$1.28B	$186,000 0.0% of portfolio	41,025	Q3 2024 Added 24.22%
VYGR Voyager Therapeutics, Inc.	$229M	$176,000 0.0% of portfolio	30,213	Q3 2024 Added 3.59%
VXRT Vaxart, Inc.	$111M	$160,000 0.0% of portfolio	188,384	Q3 2024 Reduced 4.29%
HUMA Humacyte, Inc.	$488M	$149,000 0.0% of portfolio	27,568	Q3 2024 New
NVAX Novavax Inc	$846M	$149,000 0.0% of portfolio	11,805	Q3 2024 Added 10.6%
LQDA Liquidia Corp	$798M	$144,000 0.0% of portfolio	14,400	Q3 2024 New
LEXX Lexaria Bioscience Corp.	$13M	$136,000 0.0% of portfolio	44,900	Q3 2024 Reduced 7.99%
BDTX Black Diamond Therapeutics, Inc.	$77.8M	$131,000 0.0% of portfolio	30,242	Q3 2024 Added 75.4%
KMPH Kempharm, Inc	$170M	$127,000 0.0% of portfolio	25,818	Q3 2024 Reduced 19.2%
HRTX Heron Therapeutics, Inc.	$201M	$110,000 0.0% of portfolio	55,595	Q3 2024 Added 64.36%
TSVT 2seventy Bio, Inc.	$107M	$82,000 0.0% of portfolio	17,421	Q3 2024 New
IBRX Immunity Bio, Inc.	$1.09B	$79,000 0.0% of portfolio	21,301	Q3 2024 Added 25.29%
OMGA Omega Therapeutics, Inc.	$41.2M	$72,000 0.0% of portfolio	59,474	Q3 2024 Added 55.83%
AVXL Anavex Life Sciences Corp.	$1.05B	$69,000 0.0% of portfolio	12,275	Q3 2024 New
EXAI Exscientia PLC	$593M	$65,000 0.0% of portfolio	13,371	Q3 2024 Reduced 15.51%
SLGL Sol Gel Technologies Ltd.	$25.2M	$60,000 0.0% of portfolio	88,461	Q3 2024 Reduced 9.13%
QURE Uni Qure N.V.	$824M	$58,000 0.0% of portfolio	11,916	Q3 2024 Added 15.85%
ALVR Allovir, Inc.	$44.7M	$49,000 0.0% of portfolio	60,500	Q1 2024 Added 80.92%
DMAC Dia Medica Therapeutics Inc.	$146M	$48,000 0.0% of portfolio	11,520	Q3 2024 New
ATAI Atai Life Sciences N.V.	$290M	$34,000 0.0% of portfolio	29,571	Q3 2024 Added 128.42%
ABCL Ab Cellera Biologics Inc.	$935M	$27,000 0.0% of portfolio	10,552	Q3 2024 Reduced 10.08%
CVM Cel Sci Corp	$17.3M	$23,000 0.0% of portfolio	22,444	Q3 2024 Added 6.05%
ATOS Atossa Therapeutics, Inc.	$120M	$16,000 0.0% of portfolio	10,815	Q4 2023 Reduced 10.06%
BLUE Bluebird Bio, Inc.	$696M	$14,000 0.0% of portfolio	28,710	Q3 2024 Added 3.61%
VERU Veru Inc.	$59.3M	$14,000 0.0% of portfolio	19,126	Q3 2024 New
GRTS Gritstone Bio, Inc.	$2.19M	$11,000 0.0% of portfolio	19,873	Q3 2024 Reduced 9.97%
SGMO Sangamo Therapeutics, Inc	$214M	$10,000 0.0% of portfolio	11,833	Q3 2024 Reduced 7.64%
LCTX Lineage Cell Therapeutics, Inc.	$98.5M	$9,000 0.0% of portfolio	10,507	Q3 2024 Reduced 15.31%
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	78,779	Q3 2024 Added 653.87%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.